Waleed Ghanima

Has grant

Head of Research

Norway

Research Interests

Explore related searches

Professors in Norway

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Waleed Ghanima is the Head of Research at Østfold Hospital in Norway. His research areas primarily focus on immune thrombocytopenia, evidenced by his recent articles exploring treatment efficacy, patient experiences, and comparative studies on anticoagulants. Additionally, he investigates the potential of machine learning in revolutionizing treatment for this condition.

Recent Grants

Grant: Close

Optimizing the management of patients with suspected deep venous thrombosis - the Ri-SCHEDULE study

Open Date: 2017-01-01

Close Date: 2020-01-01

Grant: Close

Improving the safety of oral anticoagulants

Open Date: 2017-01-01

Close Date: 2020-01-01

Grant: Close

Prolonging the response to anti-CD20 in immune thrombocytopenia by low-dose maintenance therapy - A randomized controlled trial

Open Date: 2015-01-01

Close Date:

Grant: Close

Improving the safety of oral anticoagulants

Open Date:

Close Date:

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

David Morrison

Lady Davis Institute for Medical Research

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Waleed Ghanima

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (16)

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports

Comparative safety and effectiveness of direct oral anticoagulants and warfarin in patients with venous thromboembolism in Finland, Norway and Sweden

A Qualitative Study on Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

Increased ultra‐large von Willebrand factor multimers in immune thrombocytopenia

Evaluating rilzabrutinib in the treatment of immune thrombocytopenia

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Could machine learning revolutionize how we treat immune thrombocytopenia?

Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway

ITP definitions: Time for an update

How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)

Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups

Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study

Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis

Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis

Collaborators (1)

David Morrison

Make your next move.